{
  "docId": "019de075-c130-77ea-b60f-b21955e0fc8e",
  "docSlug": "71c1598fd07d494c4a73d86584bdcfa9",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 39,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "The slide combines a retrospective traction report with a mission/vision statement.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/4",
  "deckHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e",
  "deckJsonHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json",
  "deckAnchorHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.06,
        "y": 0.68
      },
      "kind": "list",
      "text": "Continued advancement of internal research & discovery pipeline",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2557ff69-21a4-4f6e-b956-e5b482ae9f3f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.06,
        "y": 0.84
      },
      "kind": "list",
      "text": "$264.5M upsized financing expected to extend cash runway into 2nd half of 2025",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3b55b0a4-987f-4816-9da6-c08752a66848",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.06,
        "y": 0.76
      },
      "kind": "list",
      "text": "Continued team growth (60+ FTEs)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3c9c2fb5-8673-4bf9-adca-7ae214d68c52",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.06,
        "y": 0.6
      },
      "kind": "list",
      "text": "Nominated 3rd development candidate: NVL-330, a HER2ex20-selective inhibitor",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b30e5e99-57ab-4ae0-af51-e231ca5de650",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.06,
        "y": 0.42
      },
      "kind": "list",
      "text": "Trial initiated for parallel lead program: ALKOVE-1 Phase 1/2 study of NVL-655 for patients with advanced ALK-positive NSCLC and other solid tumors, with update on preliminary dose-escalation data expected at a medical meeting in 4Q'23",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bd623a2b-b23e-4c98-848d-347857cd8f15",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.4,
        "x": 0.06,
        "y": 0.28
      },
      "kind": "list",
      "text": "Preliminary Phase 1 data presented at EORTC-NCI-AACR: ARROS-1 Phase 1/2 study of NVL-520 for patients with advanced ROS1-positive NSCLC and other solid tumors",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "edb0b9d3-34ca-48da-9a4d-a9c1b1b40c02",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.09,
        "w": 0.335,
        "x": 0.615,
        "y": 0.498
      },
      "kind": "paragraph",
      "text": "Fully integrated pharmaceutical company with the goal of translating deep expertise in chemistry & structure-based drug design into best-in-class small molecule medicines for patients with cancer",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "60d8b639-eb35-495e-b61a-61755391e832",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.27,
        "x": 0.648,
        "y": 0.395
      },
      "kind": "paragraph",
      "text": "Discover, Develop & Deliver",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "72ed63b5-90db-479f-88b0-5e2e1c2ad7a0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.1,
        "x": 0.733,
        "y": 0.318
      },
      "kind": "title",
      "text": "Vision",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "40b59d87-7b36-4511-a8d7-e68bce78ee07",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.18,
        "x": 0.06,
        "y": 0.1
      },
      "kind": "title",
      "text": "2022 IN REVIEW",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c3ab2882-a1a0-4407-8ab2-c184e0985fe9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "0279f65c-5a52-43f8-88a1-6a0fcc7786b9",
      "evidence": "list/bullet: Trial initiated for parallel lead program: ALKOVE-1 Phase 1/2 study of NVL-655 for patients with advanced ALK-positive NSCLC and other solid tumors, with update on preliminary dose-escalation data expected a",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}